AnaptysBio Inc ANAB

Healthcare Biotechnology

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

NDAQ:ANAB - Post by User

AnaptysBio Inc

Bullboard Posts

Next >>

Post by AviseAnalyticson Jul 07, 2021 8:25am

74 Views

Post# 33504259

5 PROMISING STOCKS IN ALOPECIA AREATA

1 In 5 Americans Are Losing Their Hair...

More than 50 percent of women experience balding…

By 50 years of age, about 85 percent of men are balding….

On analysing the pipeline of Alopecia Areata, we have found these 5 stocks that are leveraging their innovative technology to achieve a much needed breakthrough. These stocks have tremendous potential and are a must watch!

$CNCE

$ANAB

$ARNA

$ARQT

Bioniz Therapeutics

https://www.aviseanalytics.com/5-promising-stocks-in-alopecia-areata/

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle